Softwr

Healthcare · head to head

Beckman Coulter DxONE vs PathAI

Beckman Coulter DxONE logo

Beckman Coulter DxONE

Healthcare

Clinical laboratory middleware and informatics from a diagnostics instrument manufacturer

From
On request
Rated
-
Full reviewWebsite
PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Beckman Coulter DxONE the rules and quality control workflows are tuned to Beckman analysers, so laboratories with a mixed Roche, Abbott and Siemens fleet get materially less coverage and typically buy vendor neutral middleware such as Data Innovations Instrument Manager instead.; PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • They diverge on capability: Beckman Coulter DxONE covers DxONE Command Central, PathAI covers AISight image management.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Beckman Coulter DxONE and PathAI actually diverge.

Attributes where Beckman Coulter DxONE and PathAI differ
AttributeBeckman Coulter DxONEPathAI
PlatformsWeb, WindowsWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Beckman Coulter DxONE

  • DxONE Command Central
  • DxONE Workflow Manager
  • REMISOL Advance
  • DxONE Inventory Manager
  • Autoverification rules
  • Quality control monitoring
  • LIS interfacing

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

What people use each for

The jobs each tool is most often brought in to do.

Beckman Coulter DxONE

  • A hospital laboratory standardising on Beckman DxC and DxI analysers that wants autoverification to release the majority of routine chemistry without technologist reviewnot PathAI
  • A low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules enginenot PathAI
  • A multi site laboratory network that needs identical autoverification rules applied consistently across every site, which REMISOL Advance is built fornot PathAI
  • A laboratory whose LIS cannot express delta checks or repeat rules and needs that logic to live in middleware insteadnot PathAI

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Beckman Coulter DxONE
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Beckman Coulter DxONE
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Beckman Coulter DxONE
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Beckman Coulter DxONE

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Beckman Coulter DxONE

  • The rules and quality control workflows are tuned to Beckman analysers, so laboratories with a mixed Roche, Abbott and Siemens fleet get materially less coverage and typically buy vendor neutral middleware such as Data Innovations Instrument Manager instead.
  • Pricing is bundled into analyser and reagent contracts rather than itemised, so a laboratory cannot compare the informatics cost against a standalone middleware quote and often does not know what it is paying for the software.
  • Because the software is tied to a reagent rental term, the real cost of switching middleware is the remaining years of the reagent commitment, not a software renewal, which locks the laboratory in far longer than a software contract would.
  • DxONE Workflow Manager and REMISOL Advance are different products with different rule engines rather than one product at two sizes, so a laboratory that grows out of Workflow Manager faces a migration and rule rewrite, not an upgrade.
  • Interface builds to the hospital LIS are professional services work quoted per interface, and laboratories consistently underestimate this line, particularly where the LIS is an older Sunquest or SCC installation.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Pricing, plan by plan

Beckman Coulter DxONE

On request
  • DxONE$undefined/year
    • Quoted as part of an analyser or reagent contract, not as standalone software
    • Priced against instrument fleet size and test volume
    • Multi year reagent rental agreements are the usual commercial vehicle

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Which should you pick?

Choose Beckman Coulter DxONE if

  • You need dxone command central.
  • You work on Web, Windows.
  • You also want dxone workflow manager.
Beckman Coulter DxONE review

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Questions people ask

Is Beckman Coulter DxONE or PathAI better?
Neither clearly leads. Beckman Coulter DxONE starts at On request and PathAI at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Beckman Coulter DxONE or PathAI?
Beckman Coulter DxONE starts at On request and PathAI at On request.
Does Beckman Coulter DxONE or PathAI run on more platforms?
Beckman Coulter DxONE runs on Web, Windows. PathAI runs on Web.
What is Beckman Coulter DxONE best used for?
Beckman Coulter DxONE is most often used for a hospital laboratory standardising on beckman dxc and dxi analysers that wants autoverification to release the majority of routine chemistry without technologist review, a low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules engine, a multi site laboratory network that needs identical autoverification rules applied consistently across every site, which remisol advance is built for, a laboratory whose lis cannot express delta checks or repeat rules and needs that logic to live in middleware instead. Of those, a hospital laboratory standardising on beckman dxc and dxi analysers that wants autoverification to release the majority of routine chemistry without technologist review and a low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules engine are not what PathAI is typically brought in for.
What can Beckman Coulter DxONE do that PathAI cannot?
Beckman Coulter DxONE covers DxONE Command Central, DxONE Workflow Manager, REMISOL Advance, DxONE Inventory Manager. PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management.

Answered from the vendors’ own pages

Beckman Coulter DxONE: Can I buy DxONE without buying Beckman analysers?

Not realistically. It is quoted as part of an instrument or reagent agreement and its value is in the depth of integration with Beckman platforms. A laboratory with other analysers should look at vendor neutral middleware.

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

Beckman Coulter DxONE: Is DxONE the same as REMISOL Advance?

No. REMISOL Advance is the on premises middleware for higher volume and multi site laboratories. DxONE Workflow Manager is a separate cloud product aimed at low volume laboratories. They are not the same rule engine.

PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

Beckman Coulter DxONE: Does Beckman publish pricing?

No. Everything is quoted, and the software cost is usually folded into a cost per reportable result on a reagent contract rather than shown as a licence fee.

PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

Beckman Coulter DxONE: Is DxONE a regulated medical device?

The middleware components carry regulatory registrations that vary by product and region. Autoverification of diagnostic results is a regulated function, so confirm the specific clearance for the module and country before deployment.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Share

Related pages

More on Beckman Coulter DxONE

More on PathAI

Keep looking

Other head to heads